Tenax Therapeutics (NASDAQ:TENX) Earns “Outperform” Rating from William Blair

Tenax Therapeutics (NASDAQ:TENX)‘s stock had its “outperform” rating reaffirmed by investment analysts at William Blair in a research note issued to investors on Monday,RTT News reports.

Separately, Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Stock Down 0.6 %

Tenax Therapeutics stock traded down $0.04 during mid-day trading on Monday, reaching $6.15. 6,451 shares of the company were exchanged, compared to its average volume of 46,103. The firm’s 50-day simple moving average is $6.45 and its two-hundred day simple moving average is $5.19. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89.

Institutional Trading of Tenax Therapeutics

Several hedge funds have recently modified their holdings of TENX. Two Sigma Investments LP purchased a new position in Tenax Therapeutics in the fourth quarter worth $84,000. Geode Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Tenax Therapeutics in the 4th quarter valued at about $166,000. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics in the third quarter valued at about $101,000. Finally, Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics during the third quarter worth about $173,000. 1.67% of the stock is owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.